These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
114 related items for PubMed ID: 10962418
1. Aprotinin administration in the pericardial cavity does not prevent platelet activation. Maquelin KN, Nieuwland R, Lentjes EG, Böing AN, Mochtar B, Eijsman L, Sturk A. J Thorac Cardiovasc Surg; 2000 Sep; 120(3):552-7. PubMed ID: 10962418 [Abstract] [Full Text] [Related]
2. Activation of fibrinolysis in the pericardial cavity after cardiopulmonary bypass. Khalil PN, Ismail M, Kalmar P, von Knobelsdorff G, Marx G. Thromb Haemost; 2004 Sep; 92(3):568-74. PubMed ID: 15351853 [Abstract] [Full Text] [Related]
3. Aprotinin administration in the pericardial cavity does not prevent platelet activation. Landis RC, Taylor KM. J Thorac Cardiovasc Surg; 2001 Aug; 122(2):405-6. PubMed ID: 11479528 [No Abstract] [Full Text] [Related]
9. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass. Wahba A, Black G, Koksch M, Rothe G, Preuner J, Schmitz G, Birnbaum DE. Thromb Haemost; 1996 May; 75(5):844-8. PubMed ID: 8725734 [Abstract] [Full Text] [Related]
10. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. J Thorac Cardiovasc Surg; 1990 May; 99(5):788-96; discussion 796-7. PubMed ID: 1691806 [Abstract] [Full Text] [Related]
13. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin. Santamaría A, Mateo J, Muñíz-Díaz E, Oliver A, Murillo J, Litvan H, Souto JC, Fontcuberta J. Haematologica; 2000 Apr; 85(4):381-5. PubMed ID: 10756363 [Abstract] [Full Text] [Related]
15. Topical use of aprotinin in coronary artery bypass surgery. Mand'ák J, Lonský V, Dominik J. Acta Medica (Hradec Kralove); 1999 Apr; 42(4):139-44. PubMed ID: 10812681 [Abstract] [Full Text] [Related]
16. Platelet dysfunction after normothermic cardiopulmonary bypass in children: effect of high-dose aprotinin. Flaujac C, Pouard P, Boutouyrie P, Emmerich J, Bachelot-Loza C, Lasne D. Thromb Haemost; 2007 Aug; 98(2):385-91. PubMed ID: 17721621 [Abstract] [Full Text] [Related]
17. Activation of hemostasis during cardiopulmonary bypass and pediatric aprotinin dosage. Mössinger H, Dietrich W. Ann Thorac Surg; 1998 Jun; 65(6 Suppl):S45-50; discussion S50-1, S74-6. PubMed ID: 9647138 [Abstract] [Full Text] [Related]
18. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol). Lu H, Soria C, Commin PL, Soria J, Piwnica A, Schumann F, Regnier O, Legrand Y, Caen JP. Thromb Haemost; 1991 Dec 02; 66(6):633-7. PubMed ID: 1724577 [Abstract] [Full Text] [Related]
19. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. Lavee J, Raviv Z, Smolinsky A, Savion N, Varon D, Goor DA, Mohr R. Ann Thorac Surg; 1993 Jan 02; 55(1):114-9. PubMed ID: 7678061 [Abstract] [Full Text] [Related]